RecruitingPhase 2Phase 3NCT06252961
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 3- or 5- Day Course of Levamisole 2.5 mg/kg in Subjects With Loa Loa Microfilaremia
Sponsor
Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Enrollment
99 participants
Start Date
Jun 21, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria6
- Consent informed, written, signed and dated
- Women or men aged 18 to 65 years inclusive
- Carrier of L. loa microfilaremia
- Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 90 kg
- In good health, as determined by medical questionnaire and general clinical examination
- Absence of acute or chronic infection :
Exclusion Criteria14
- Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of levamisole or placebo)
- Any vaccination within 4 weeks previous to this study
- Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)
- Treatment with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, and gold salts: whether it was long-term treatment, or treatment given as a single dose 10 days before the start of treatment for the clinical trial (precaution with regard to the risk of agranulocytosis of immuno-allergic or toxic origin)
- Known immunosuppressive pathology (by self-report)
- Past or present history of neurological (including epilepsy) or neuropsychiatric disease
- History of agranulocytosis
- Use of cocaine or other drugs of abuse in the 72 hours preceding administration of the trial treatment, as determined by history during the medical interview
- Any condition, in the opinion of the investigator, that exposes the subject to undue risk
- Known intolerance to levamisole
- Subjects who donated blood in the previous 8 weeks to study entry, with a standard volume (\> 500 mL)
- On clinical examination: symptoms, physical signs or laboratory findings suggestive of systemic disorders, including disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other abnormalities that could interfere with the interpretation of trial results. The physician may then give a favorable or unfavorable opinion on the participant's inclusion.
- Ivermectin and/or levamisole taken in the last six months; and/or mebendazole or albendazole taken in the last month
- Pregnant and/or breast-feeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLevamisole 3 days
Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
DRUGLevamisole 5 days
Levamisole for 5 days (2,5 mg/kg)
DRUGPlacebo
Placebo for 5 days
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06252961